论文部分内容阅读
【目的】评价伊立替康(CPT-11,irinotecan)联合卡培他滨(capecitabine)方案治疗晚期结直肠癌的近期疗效与不良反应。【方法】伊立替康150 mg/m2静脉滴注d1,d8,卡培他滨1 000 mg/m2,口服,2次/天,d1~14,治疗24例术后曾接受过OXA+5-Fu/LV,HCPT+5-Fu/LV方案化疗后复发和(或)转移的结直肠癌,每3周重复,至少完成2个周期。【结果】全组共化疗108周期,平均4.5周期/例。24例化疗后完全缓解(CR)1例(4.2%),部分缓解(PR)10例(41.7%),疾病稳定(SD)10例(41.7%),疾病进展(PD)3例(12.5%),有效率(RR)45.8%。中位生存期11.2个月。主要不良反应为白细胞下降(62.5%)、迟发性腹泻(58.3%)、手足综合征(33.3%),无化疗相关死亡。【结论】伊立替康联合卡培他滨方案治疗晚期结直肠癌疗效高,毒副作用可较好耐受。
【Objective】 To evaluate the short-term effects and side effects of irinotecan plus capecitabine in the treatment of advanced colorectal cancer. 【Methods】 The irinotecan 150 mg / m2 intravenous infusion d1, d8, capecitabine 1000 mg / m2 orally, 2 times / day, d1 ~ 14, 24 patients had received OXA + 5- Fu / LV, HCPT + 5-Fu / LV regimen Recurrence and / or metastatic colorectal cancer after chemotherapy, repeated every 3 weeks, at least 2 cycles completed. 【Results】 The whole group of 108 cycles of chemotherapy, an average of 4.5 cycles / case. Among the 24 patients with complete remission (CR), 1 (4.2%) achieved complete remission (CR), 10 (41.7%) had partial remission (PR), 10 (41.7%) had stable disease (SD) ), Efficiency (RR) 45.8%. Median survival was 11.2 months. The main adverse reactions were leukopenia (62.5%), delayed diarrhea (58.3%), hand-foot syndrome (33.3%), and no chemotherapy-related death. 【Conclusion】 The combination of irinotecan and capecitabine can effectively treat advanced colorectal cancer with better toxic side effects.